Gammacore Sapphire CV (COVID-19)
Notice: Gammacore Sapphire CV treatment only available via prescription to patients of record
Noninvasive Covid-19 Respiratory Treatment Device
The FDA has issued an Emergency Use Authorization (EUA) in July of 2020 authorizing the use of GammaCore Sapphire™ CV noninvasive vagus nerve stimulation (nVNS) at home or in a healthcare setting to acutely treat adult patients with known or suspected COVID-19 who are experiencing an exacerbation of asthma-related dyspnea and reduced airflow and for whom approved drug therapies are not tolerated or provide insufficient symptom relief.
This novel device works by stimulating the vagal nerve in a specific manner that results in opening of the bronchial passages. Treatments are applied to the vagal nerve on the neck multiple times daily. Health Partners LLC is an authorized prescriber of this device to patients with known or suspected Covid, experiencing respiratory symptoms meeting the above criteria.